Epidermolysis Bullosa News and Research

RSS

RegeneRx receives patent for Tβ4 to prevent immunological responses from toxic agents

RegeneRx Biopharmaceuticals, Inc. announced that the Company received a patent in Australia using thymosin beta 4 (Tβ4), and various fragments and anologues of Tβ4, to treat or prevent biological and immunological responses to reactive chemical, biological or toxic agents.

2 Dec 2010

Scientists identify signaling pathway and receptor for thymosin beta 4

RegeneRx Biopharmaceuticals, Inc. nnounced that scientists have identified a long sought-after extracellular signaling pathway and receptor for thymosin beta 4 (Tβ4). The observation that Tβ4 increases cell surface ATP (energy produced by cells), could explain its ability to protect and regenerate tissue after ischemic injury and hypoxia (oxygen deficiency).

30 Nov 2010

RegeneRx announces positive results from RGN-259 non-clinical study for Dry Eye Syndrome

RegeneRx Biopharmaceuticals, Inc. today announced the results of its first non-clinical dry eye study using RGN-259, RegeneRx's ophthalmic, preservative-free eye drop for the treatment of Dry Eye Syndrome (DES). In the study, animals were treated with RGN-259, a vehicle control and a positive control, doxycycline.

2 Nov 2010

Thymosin beta 4 is essential to healthy heart development, embryonic survival: Research

RegeneRx Biopharmaceuticals, Inc. today announced that a research team from the Molecular Medicine Unit at UCL-Institute of Child Health in London reported preclinical findings that Thymosin beta 4, is essential to healthy heart development and embryonic survival.

2 Aug 2010

Thymosin beta 4 improves neurological functional outcome after embolic stroke: Researchers

RegeneRx Biopharmaceuticals, Inc. today announced a research team from the Henry Ford Hospital in Detroit, MI, reported that Thymosin beta 4, administered to rats after embolic stroke, improved neurological functional outcome compared to control animals.

20 Jul 2010

Sangamo's ZFP Therapeutics technology highlighted at ASGCT Annual Meeting

Sangamo BioSciences, Inc. announced today that data from research and preclinical programs focused on the development of zinc finger DNA-binding protein Therapeutics were described in fifteen presentations given by Sangamo scientists and collaborators at the 13th Annual Meeting of the American Society of Gene and Cell Therapy.

24 May 2010

RegeneRx Biopharmaceuticals prices underwritten public offering at $0.41 per unit

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company focused on the development of a novel therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair and regeneration in cardiovascular diseases, central nervous system injuries, ophthalmic indications and dermal wounds, announced the pricing of its previously announced underwritten public offering of 11,500,000 units of its securities at a public offering price of $0.41 per unit.

19 May 2010

RegeneRx Biopharmaceuticals proposes common stock public offering

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company focused on the development of a novel therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair and regeneration in cardiovascular diseases, central nervous system injuries, ophthalmic indications and dermal wounds, announced today that it intends to offer units consisting of shares of its common stock and warrants to purchase shares of its common stock in a public offering.

17 Apr 2010

RTI Biologics donates Matrix HD to treat eight-year-old with recessive dystrophic EB

RTI Biologics Inc. (RTI), the Florida-based processor of orthopedic, dental, hernia and other biologic implants, has donated a sterilized dermis allograft, Matrix HD™, to treat an eight-year old patient with a rare skin disease called recessive dystrophic epidermolysis bullosa (EB).

29 Jan 2010

People with severe EBS at increased risk of skin cancer, say scientists

UK scientists have discovered the link between people with the skin blistering disease Epidermolysis Bullosa Simplex-Dowling-Meara, (EBS -DM) - and tumour growth, according to research published in Journal of Investigative Dermatology today (Monday).

25 Nov 2009

Clinical study data of Thymosin beta 4 presented

REGENERX BIOPHARMACEUTICALS, INC. today reported on several clinical studies with Thymosin beta 4 (Tβ4) presented the Second International Symposium on Thymosins in Health and Disease, in Catania, Italy.

3 Oct 2009

Stem cells derived from bone marrow may offer novel therapeutic option for epidermolysis bullosa

Stem cells derived from bone marrow may serve as a novel therapeutic option to treat a disease called epidermolysis bullosa (EB), a disorder characterized by extraordinarily fragile skin, according to a study prepublished online in Blood, the official journal of the American Society of Hematology.

5 Dec 2008

U of M sets new standard of care for recessive dystrophic epidermolysis bullosa

Physicians at the University of Minnesota and University of Minnesota Children's Hospital, Fairview have set the path to a cure for a young boy's fatal genetic skin disease, recessive dystrophic epidermolysis bullosa (RDEB), by using a cord blood and bone marrow transplant. Nate Liao, a 25-month-old from Clarksburg, N.J., underwent the experimental therapy in October 2007.

3 Jun 2008

Epidermolysis Bullosa News and Research

RegeneRx receives patent for Tβ4 to prevent immunological responses from toxic agents

Scientists identify signaling pathway and receptor for thymosin beta 4

RegeneRx announces positive results from RGN-259 non-clinical study for Dry Eye Syndrome

Thymosin beta 4 is essential to healthy heart development, embryonic survival: Research

Thymosin beta 4 improves neurological functional outcome after embolic stroke: Researchers

Sangamo's ZFP Therapeutics technology highlighted at ASGCT Annual Meeting

RegeneRx Biopharmaceuticals prices underwritten public offering at $0.41 per unit

RegeneRx Biopharmaceuticals proposes common stock public offering

RTI Biologics donates Matrix HD to treat eight-year-old with recessive dystrophic EB

People with severe EBS at increased risk of skin cancer, say scientists

Clinical study data of Thymosin beta 4 presented

Stem cells derived from bone marrow may offer novel therapeutic option for epidermolysis bullosa

U of M sets new standard of care for recessive dystrophic epidermolysis bullosa

Broccoli shows benefits for epidermolysis bullosa simplex

First systemic therapy for fatal childhood disease - recessive dystrophic epidermolysis bullosa

Stem cells to treat damaged eyes and a rare skin disorder

UK experts call for debate on euthanasia for seriously disabled newborns

New gene therapy maybe useful for treating muscular dystrophy

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News